JP2017513955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513955A5 JP2017513955A5 JP2017507914A JP2017507914A JP2017513955A5 JP 2017513955 A5 JP2017513955 A5 JP 2017513955A5 JP 2017507914 A JP2017507914 A JP 2017507914A JP 2017507914 A JP2017507914 A JP 2017507914A JP 2017513955 A5 JP2017513955 A5 JP 2017513955A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- purin
- dihydroxytetrahydrofuran
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 120
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 96
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 94
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 34
- 125000001424 substituent group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 23
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 16
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- -1 (Methylsulfonyl) methyl Chemical group 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 10
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- QMCUISJHXICPLC-XNIJJKJLSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=C(C=CC=C1F)F)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=C(C=CC=C1F)F)O)O QMCUISJHXICPLC-XNIJJKJLSA-N 0.000 claims 2
- OGXXBFXUZNNBBS-UQAWHXBNSA-N O[C@@H]1[C@@H](COC(C(O)=O)C(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C(N[C@@H]3CCOC3)N=C(Cl)N=C12 Chemical compound O[C@@H]1[C@@H](COC(C(O)=O)C(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C(N[C@@H]3CCOC3)N=C(Cl)N=C12 OGXXBFXUZNNBBS-UQAWHXBNSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- OYYIRWXXCQBYJG-QLRVTQMJSA-N 2-[[(1R,2R,3S,4R)-4-(5-chloro-4-oxoquinazolin-3-yl)-2,3-dihydroxycyclopentyl]methoxy]-2-phosphonoacetic acid Chemical compound ClC1=C2C(N(C=NC2=CC=C1)[C@H]1[C@@H]([C@@H]([C@H](C1)COC(C(=O)O)P(=O)(O)O)O)O)=O OYYIRWXXCQBYJG-QLRVTQMJSA-N 0.000 claims 1
- NNACJYKNBNMOIB-FDGLDMCPSA-N 2-[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(4-hydroxypiperidin-1-yl)purin-9-yl]oxolan-2-yl]methoxy]-2-phosphonoacetic acid Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)N1CCC(CC1)O)COC(C(=O)O)P(=O)(O)O NNACJYKNBNMOIB-FDGLDMCPSA-N 0.000 claims 1
- KJEXWSKRPPXAMG-XNIJJKJLSA-N 2-[[(2R,3S,4R,5R)-5-(6-amino-2-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-2-[(4-fluorophenyl)methyl]propanedioic acid Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)F)O)O KJEXWSKRPPXAMG-XNIJJKJLSA-N 0.000 claims 1
- YXMCFEMTFYAHFD-OSWLWWHVSA-N C(C)(=O)NNC(C(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)P(O)(O)=O)=O Chemical compound C(C)(=O)NNC(C(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)P(O)(O)=O)=O YXMCFEMTFYAHFD-OSWLWWHVSA-N 0.000 claims 1
- HDMQNESUKKEGDK-HTTXCKMZSA-N C(C)(C)(C)OC(C(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)OC)OC)P(O)(O)=O)=O Chemical compound C(C)(C)(C)OC(C(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)OC)OC)P(O)(O)=O)=O HDMQNESUKKEGDK-HTTXCKMZSA-N 0.000 claims 1
- MMYSSOQJLSGEIO-RTAOWTGSSA-N C(C)NC(C(OC[C@@H]1[C@H]([C@H]([C@@H](C1)N1C2=NC=NC(=C2N=C1)NCC)O)O)P(O)(O)=O)=O Chemical compound C(C)NC(C(OC[C@@H]1[C@H]([C@H]([C@@H](C1)N1C2=NC=NC(=C2N=C1)NCC)O)O)P(O)(O)=O)=O MMYSSOQJLSGEIO-RTAOWTGSSA-N 0.000 claims 1
- JJTMJMCSFXBNRE-VCKWHPSQSA-N C(C1=CC=CC=C1)(=O)NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O Chemical compound C(C1=CC=CC=C1)(=O)NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O JJTMJMCSFXBNRE-VCKWHPSQSA-N 0.000 claims 1
- FWWPZKBZBGKNPG-PNXMHIEFSA-N CC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)C Chemical compound CC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)C FWWPZKBZBGKNPG-PNXMHIEFSA-N 0.000 claims 1
- DDRJOQIPWNVAIN-UQALVKDESA-N CCNC(=O)C(OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)N(C)C1=O)P(O)(O)=O Chemical compound CCNC(=O)C(OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)N(C)C1=O)P(O)(O)=O DDRJOQIPWNVAIN-UQALVKDESA-N 0.000 claims 1
- BFHYAOVYTYZXAQ-HEOLNDPQSA-N CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N)P(O)(O)=O Chemical compound CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N)P(O)(O)=O BFHYAOVYTYZXAQ-HEOLNDPQSA-N 0.000 claims 1
- MAWBBBBUAWAYIY-RIEBNTRSSA-N CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2NC1CCCC1)P(O)(O)=O Chemical compound CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2NC1CCCC1)P(O)(O)=O MAWBBBBUAWAYIY-RIEBNTRSSA-N 0.000 claims 1
- IXBOQMWWBLJCNG-YRDFTPMFSA-N CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N[C@@H]1CCOC1)P(O)(O)=O Chemical compound CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N[C@@H]1CCOC1)P(O)(O)=O IXBOQMWWBLJCNG-YRDFTPMFSA-N 0.000 claims 1
- IXBOQMWWBLJCNG-AIJVHSERSA-N CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N[C@H]1CCOC1)P(O)(O)=O Chemical compound CCOC(=O)C(OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1N=NC2=C1N=C(Cl)N=C2N[C@H]1CCOC1)P(O)(O)=O IXBOQMWWBLJCNG-AIJVHSERSA-N 0.000 claims 1
- 229940127272 CD73 inhibitor Drugs 0.000 claims 1
- HBNCWUFGFIVBQK-QWKSCMCOSA-N CNC(=O)C(OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)N(C)C1=O)P(O)(O)=O Chemical compound CNC(=O)C(OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)N(C)C1=O)P(O)(O)=O HBNCWUFGFIVBQK-QWKSCMCOSA-N 0.000 claims 1
- RBLJDONPZPVMLS-QHQIBUKQSA-N COC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)OC Chemical compound COC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)OC RBLJDONPZPVMLS-QHQIBUKQSA-N 0.000 claims 1
- NKHFMWKHXYOSJE-SDTWEEQHSA-N ClC1=C2C(N(C=NC2=CC=C1)[C@H]1[C@@H]([C@@H]([C@H](C1)COC(C(=O)O)C(=O)O)O)O)=O Chemical compound ClC1=C2C(N(C=NC2=CC=C1)[C@H]1[C@@H]([C@@H]([C@H](C1)COC(C(=O)O)C(=O)O)O)O)=O NKHFMWKHXYOSJE-SDTWEEQHSA-N 0.000 claims 1
- KDAUBZMRXUEEIY-IOSLPCCCSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)C)O)O)NC Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)C)O)O)NC KDAUBZMRXUEEIY-IOSLPCCCSA-N 0.000 claims 1
- PWSPRWKVAKSRBN-QTQZEZTPSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)F)O)O)NC1CCCC1 Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)F)O)O)NC1CCCC1 PWSPRWKVAKSRBN-QTQZEZTPSA-N 0.000 claims 1
- OGXXBFXUZNNBBS-XLZJSAHRSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O)N[C@@H]1COCC1 Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O)N[C@@H]1COCC1 OGXXBFXUZNNBBS-XLZJSAHRSA-N 0.000 claims 1
- XVPMURAJTFPVRM-JPJRCZBHSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)Cl Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)Cl XVPMURAJTFPVRM-JPJRCZBHSA-N 0.000 claims 1
- SSYZTARPABQFID-QHQIBUKQSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)OCC Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)P(=O)(O)O)O)O)OCC SSYZTARPABQFID-QHQIBUKQSA-N 0.000 claims 1
- JGTWTQBQBGKBFZ-DXXSKVHTSA-N NC1=C2N=CN(C2=NC(=N1)C#N)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)OC(C)(C)C)P(O)(O)=O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)C#N)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)OC(C)(C)C)P(O)(O)=O)O)O JGTWTQBQBGKBFZ-DXXSKVHTSA-N 0.000 claims 1
- ZZNWMLAVCIQQLD-ZKUZGDEQSA-N NC1=C2N=CN(C2=NC(=N1)C)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)C)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O ZZNWMLAVCIQQLD-ZKUZGDEQSA-N 0.000 claims 1
- CIVPXOCMWPFMIF-IWCJZZDYSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=C(C=CC=C1)S(=O)(=O)C)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=C(C=CC=C1)S(=O)(=O)C)O)O CIVPXOCMWPFMIF-IWCJZZDYSA-N 0.000 claims 1
- MYUXBGBQHXGNLZ-XNIJJKJLSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC(=CC(=C1)F)F)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC(=CC(=C1)F)F)O)O MYUXBGBQHXGNLZ-XNIJJKJLSA-N 0.000 claims 1
- UWPWDHNHBVJIPL-LSCFUAHRSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)C#N)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)C#N)O)O UWPWDHNHBVJIPL-LSCFUAHRSA-N 0.000 claims 1
- BOVGAKLPQQBCFB-XNIJJKJLSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)Cl)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)Cl)O)O BOVGAKLPQQBCFB-XNIJJKJLSA-N 0.000 claims 1
- ZFZKPWFNIIBZJD-XNIJJKJLSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=CC=C1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=CC=C1)O)O ZFZKPWFNIIBZJD-XNIJJKJLSA-N 0.000 claims 1
- AKQLZWWBBFMBMO-SDBHATRESA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=NC=CC=C1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=NC=CC=C1)O)O AKQLZWWBBFMBMO-SDBHATRESA-N 0.000 claims 1
- GZBUYOTUXSRKEE-QYVSTXNMSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1CC1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1CC1)O)O GZBUYOTUXSRKEE-QYVSTXNMSA-N 0.000 claims 1
- FGAFHLCJLQFWAP-ZRFIDHNTSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC=1SC=CN1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)CC=1SC=CN1)O)O FGAFHLCJLQFWAP-ZRFIDHNTSA-N 0.000 claims 1
- GAXFSNUKRJNBBJ-IOSLPCCCSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)COC)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)COC)O)O GAXFSNUKRJNBBJ-IOSLPCCCSA-N 0.000 claims 1
- QVERRRVPLJPAII-LSCFUAHRSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)COCC1=CC=CC=C1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(C(=O)O)COCC1=CC=CC=C1)O)O QVERRRVPLJPAII-LSCFUAHRSA-N 0.000 claims 1
- VNDRHKSOWDUKOB-BHBWVORQSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O VNDRHKSOWDUKOB-BHBWVORQSA-N 0.000 claims 1
- LBYMBTPZPDLDBZ-CFGMHQHXSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@H](C(=O)O)P(=O)(O)O)O)O LBYMBTPZPDLDBZ-CFGMHQHXSA-N 0.000 claims 1
- LBYMBTPZPDLDBZ-KXSYMAMXSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O LBYMBTPZPDLDBZ-KXSYMAMXSA-N 0.000 claims 1
- XYAVCQTXWJKTHK-QHQIBUKQSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CSC(C(=O)OCC)P(O)(O)=O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CSC(C(=O)OCC)P(O)(O)=O)O)O XYAVCQTXWJKTHK-QHQIBUKQSA-N 0.000 claims 1
- VJIZTMICECSZHQ-PTPKGGSUSA-N NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC(=O)O)(C(=O)OCC)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC(=O)O)(C(=O)OCC)P(=O)(O)O)O)O VJIZTMICECSZHQ-PTPKGGSUSA-N 0.000 claims 1
- SGCANUARCJWKQX-KXSYMAMXSA-N NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O SGCANUARCJWKQX-KXSYMAMXSA-N 0.000 claims 1
- VJIZTMICECSZHQ-BFDBYCNMSA-N NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC(=O)O)(C(=O)OCC)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)F)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC(=O)O)(C(=O)OCC)P(=O)(O)O)O)O VJIZTMICECSZHQ-BFDBYCNMSA-N 0.000 claims 1
- AJCUHKYNVWGAMK-CFGMHQHXSA-N NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@H](C(=O)O)P(=O)(O)O)O)O AJCUHKYNVWGAMK-CFGMHQHXSA-N 0.000 claims 1
- AJCUHKYNVWGAMK-KXSYMAMXSA-N NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)I)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@H](C(=O)O)P(=O)(O)O)O)O AJCUHKYNVWGAMK-KXSYMAMXSA-N 0.000 claims 1
- IIOWKKLLJJXIDK-OAPDWXTOSA-N NC1=C2N=CN(C2=NC(=N1)SC)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)OCC)P(O)(O)=O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)SC)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)OCC)P(O)(O)=O)O)O IIOWKKLLJJXIDK-OAPDWXTOSA-N 0.000 claims 1
- DYFWYSSWTRWBDC-DZUKYTIJSA-N NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)NO)P(O)(O)=O)O)O Chemical compound NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)NO)P(O)(O)=O)O)O DYFWYSSWTRWBDC-DZUKYTIJSA-N 0.000 claims 1
- LTQZCPJUUPDELT-RPKMEZRRSA-N NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)C(=O)O)O)O LTQZCPJUUPDELT-RPKMEZRRSA-N 0.000 claims 1
- JDSZIPBOWSSAOP-QHQIBUKQSA-N NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)CSC(C(=O)OC)P(O)(O)=O)O)O Chemical compound NC1=C2N=CN(C2=NC=N1)[C@H]1[C@@H]([C@@H]([C@H](O1)CSC(C(=O)OC)P(O)(O)=O)O)O JDSZIPBOWSSAOP-QHQIBUKQSA-N 0.000 claims 1
- AFFILDHYLOSONF-HEOLNDPQSA-N NC=1C2=C(N=C(N1)Br)N(N=N2)[C@H]2[C@@H]([C@@H]([C@H](C2)COC(C(=O)OCC)P(O)(O)=O)O)O Chemical compound NC=1C2=C(N=C(N1)Br)N(N=N2)[C@H]2[C@@H]([C@@H]([C@H](C2)COC(C(=O)OCC)P(O)(O)=O)O)O AFFILDHYLOSONF-HEOLNDPQSA-N 0.000 claims 1
- OFRRTZLVHRSMMO-DCEZOGAWSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C(N(C(C=C1)=O)C)=O)CO[C@@H](C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C(N(C(C=C1)=O)C)=O)CO[C@@H](C(=O)O)P(=O)(O)O OFRRTZLVHRSMMO-DCEZOGAWSA-N 0.000 claims 1
- OFRRTZLVHRSMMO-NAHXDTDZSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C(N(C(C=C1)=O)C)=O)CO[C@H](C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C(N(C(C=C1)=O)C)=O)CO[C@H](C(=O)O)P(=O)(O)O OFRRTZLVHRSMMO-NAHXDTDZSA-N 0.000 claims 1
- XOTGQOBBWXNESB-JPJRCZBHSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC(=NC(=C2N=C1)NO)I)COC(C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC(=NC(=C2N=C1)NO)I)COC(C(=O)O)P(=O)(O)O XOTGQOBBWXNESB-JPJRCZBHSA-N 0.000 claims 1
- ABNPHTLAJHVJGX-JTPBVDGGSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC(C)C)COC(C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC(C)C)COC(C(=O)O)P(=O)(O)O ABNPHTLAJHVJGX-JTPBVDGGSA-N 0.000 claims 1
- FMSLMPQVLVZWID-QHQIBUKQSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC)COC(C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC)COC(C(=O)O)P(=O)(O)O FMSLMPQVLVZWID-QHQIBUKQSA-N 0.000 claims 1
- BMLJLDZEZRMGAF-CMAHQRSQSA-N O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC1=CC=CC=C1)COC(C(=O)O)P(=O)(O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NC1=CC=CC=C1)COC(C(=O)O)P(=O)(O)O BMLJLDZEZRMGAF-CMAHQRSQSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 0 CN(CC(*C1*)C(*)C1O*)CC(*)(*)* Chemical compound CN(CC(*C1*)C(*)C1O*)CC(*)(*)* 0.000 description 7
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984659P | 2014-04-25 | 2014-04-25 | |
| US61/984,659 | 2014-04-25 | ||
| US201462051529P | 2014-09-17 | 2014-09-17 | |
| US62/051,529 | 2014-09-17 | ||
| PCT/US2015/027235 WO2015164573A1 (en) | 2014-04-25 | 2015-04-23 | Purine derivatives as cd73 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513955A JP2017513955A (ja) | 2017-06-01 |
| JP2017513955A5 true JP2017513955A5 (enExample) | 2018-06-07 |
| JP6657182B2 JP6657182B2 (ja) | 2020-03-04 |
Family
ID=53175630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507914A Active JP6657182B2 (ja) | 2014-04-25 | 2015-04-23 | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10654884B2 (enExample) |
| EP (1) | EP3134411B1 (enExample) |
| JP (1) | JP6657182B2 (enExample) |
| MA (1) | MA39986A (enExample) |
| WO (1) | WO2015164573A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10167302B2 (en) * | 2014-05-23 | 2019-01-01 | University College Cork | Phosphonate nucleosides useful in the treatment of viral diseases |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| LT3221346T (lt) | 2014-11-21 | 2020-11-10 | Bristol-Myers Squibb Company | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis |
| CA3151595A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| TW201811782A (zh) * | 2016-08-26 | 2018-04-01 | 日商田邊三菱製藥股份有限公司 | 二環式含氮雜環化合物 |
| US10472364B2 (en) | 2016-09-09 | 2019-11-12 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
| CN110022881B (zh) * | 2016-11-18 | 2023-05-02 | 艾库斯生物科学有限公司 | Cd73介导的免疫抑制的抑制剂 |
| EP3558998A4 (en) * | 2016-12-22 | 2020-06-10 | Calithera Biosciences, Inc. | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE |
| KR102584011B1 (ko) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | 암 치료를 위한 조성물 및 방법 |
| EP3600273A4 (en) * | 2017-03-31 | 2021-01-20 | Peloton Therapeutics, Inc. | CD73 INHIBITORS AND USES THEREOF |
| KR101841604B1 (ko) | 2017-04-26 | 2018-03-26 | 순천대학교 산학협력단 | 퍼푸린을 유효성분으로 포함하는 우울증 및 불안증의 예방 또는 치료용 조성물 |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| EA039042B1 (ru) * | 2017-09-08 | 2021-11-25 | Калитера Байосайенсиз, Инк. | Ингибиторы эктонуклеотидазы и способы их применения |
| BR112020006809A2 (pt) | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| WO2019090111A1 (en) * | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| SG11202007199XA (en) | 2018-03-09 | 2020-09-29 | Phanes Therapeutics Inc | Anti-cd73 antibodies and uses thereof |
| WO2019173682A1 (en) * | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| WO2019213174A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| PT3807316T (pt) | 2018-06-18 | 2024-07-29 | Innate Pharma | Composições e métodos para tratamento de cancro |
| JP7538047B2 (ja) * | 2018-06-21 | 2024-08-21 | アンテンジーン セラピューティクス リミテッド | エクトヌクレオチダーゼ阻害剤及びその使用方法 |
| ES3053198T3 (en) | 2018-08-27 | 2026-01-20 | Arcus Biosciences Inc | Cd73 inhibitors |
| CN112638389A (zh) * | 2018-08-28 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | Cd73抑制剂及其治疗用途 |
| EP3849992A4 (en) | 2018-09-11 | 2022-06-29 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| CN111184698A (zh) * | 2018-11-15 | 2020-05-22 | 和记黄埔医药（上海）有限公司 | 呋喹替尼制剂及其应用 |
| WO2020123772A1 (en) * | 2018-12-13 | 2020-06-18 | Arcus Biosciences, Inc. | Solid forms of a cd73 inhibitor and the use thereof |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| CN112955444B (zh) * | 2019-01-22 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| US20220160747A1 (en) * | 2019-03-20 | 2022-05-26 | Korea Research Institute Of Chemical Technology | Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient |
| CN113874397A (zh) | 2019-03-29 | 2021-12-31 | 艾库斯生物科学有限公司 | 利用鉴定的腺苷指纹治疗癌症 |
| CN113905743B (zh) * | 2019-03-29 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | Cd73抑制剂及其治疗用途 |
| WO2020210938A1 (en) * | 2019-04-15 | 2020-10-22 | Bioardis Llc | Quinazoline derivatives as cd73 inhibitors |
| EP3986894A4 (en) * | 2019-06-20 | 2023-08-09 | Antengene Therapeutics Limited | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF |
| JP7557522B2 (ja) * | 2019-07-16 | 2024-09-27 | オリック ファーマシューティカルズ，インク． | Ｃｄ７３阻害剤 |
| BR112022006791A2 (pt) | 2019-10-09 | 2022-06-28 | Bayer Ag | Novos compostos heteroaril-triazol como pesticidas |
| EP4051688B1 (en) * | 2019-10-30 | 2025-04-23 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| WO2021257643A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
| CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4401025B2 (ja) | 1998-07-01 | 2010-01-20 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 分子間相互作用の腔誘導アロステリック修飾および同一の効果を持つ化合物の同定方法 |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| EP1860113A1 (en) * | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| US8956824B2 (en) | 2006-12-04 | 2015-02-17 | British Columbia Cancer Agency Branch | Methods for identifying allosteric modulators of ship polypeptides |
| US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| WO2012031320A1 (en) | 2010-09-06 | 2012-03-15 | Peter Maccallum Cancer Institute | Cancer diagnostic |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
-
2015
- 2015-04-23 EP EP15722317.3A patent/EP3134411B1/en active Active
- 2015-04-23 MA MA039986A patent/MA39986A/fr unknown
- 2015-04-23 US US15/306,197 patent/US10654884B2/en active Active
- 2015-04-23 WO PCT/US2015/027235 patent/WO2015164573A1/en not_active Ceased
- 2015-04-23 JP JP2017507914A patent/JP6657182B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513955A5 (enExample) | ||
| ES2815373T3 (es) | Procedimiento de compuesto antifúngico | |
| ES2821021T3 (es) | Procedimiento de compuestos antifúngicos | |
| JP2006504658A5 (enExample) | ||
| AU2016377364A1 (en) | 4-amino-2-(1H-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1H-indazol-3-yl) derivatives as cGMP modulators for treating cardiovascular diseases | |
| JP2010504346A5 (enExample) | ||
| AU2009282478A1 (en) | Flavin derivatives | |
| JP2016536288A5 (enExample) | ||
| JP2011500758A5 (enExample) | ||
| JP2015519401A5 (enExample) | ||
| JP2007512370A5 (enExample) | ||
| JP2022508953A (ja) | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 | |
| JP2010138190A5 (enExample) | ||
| NZ600881A (en) | Pyrazole derivatives as jak inhibitors | |
| JP2011526917A5 (enExample) | ||
| JP2018514544A5 (enExample) | ||
| JP2009542716A5 (enExample) | ||
| NZ604074A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| JP2009504764A5 (enExample) | ||
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| JP2017516826A5 (enExample) | ||
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2021519785A (ja) | 共有結合性メニン阻害剤としてのピペリジン化合物 | |
| JP2018530582A5 (enExample) | ||
| RU2010130418A (ru) | Производные 4-аминопиримидина |